COVID-19 Drives a Surge in Demand, But What is the Long Term Impact? The Microbiology Lab May Disappear While Multiplex Takes Center Stage
The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe.
Find out what the numbers are in this informative report, and find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.
Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report.
A range of dynamic trends are pushing market growth and company valuations.
Pathogen evolution and pandemics;
Biotechnology advances in genetics;
The rise of rapid testing.
Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.
The report has hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available.
Key Topics Covered:
1 Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19
2 Guide for Executives, Marketing, Sales and Business Development Staff
3 Guide for Management Consultants and Investment Advisors
4 Introduction and Market Definition 4.1 What is Molecular Diagnostics 4.2 The Diagnostics Revolution 4.3 Market Definition 4.3.1 Revenues 4.4 Methodology 4.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective 4.5.1 U.S. Medicare Expenditures for Clinical Testing
5 The Infectious Diseases - Market Analysis by Disease 5.1 HIV - Human Immunodeficiency Virus (AIDS) 5.1.1 Virology 220.127.116.11 Classification 18.104.22.168 Structure and genome 22.214.171.124 Tropism 126.96.36.199 Replication cycle 188.8.131.52 Genetic variability 5.1.2 Diagnosis 5.1.3 Testing 184.108.40.206 Antibody tests 220.127.116.11 Point of Care Tests (POCT) 18.104.22.168 Antigen Tests 22.214.171.124 Nucleic acid-based tests (NAT) 126.96.36.199 Other tests used in HIV treatment 5.1.4 Market Opportunity Analysis 5.2 HBV - Hepatitis B 5.2.1 Virology 188.8.131.52 Genome 184.108.40.206 Pathogenesis 220.127.116.11 Hepatitis B virus replication 18.104.22.168 Serotypes and genotypes 5.2.2 Mechanisms 5.2.3 Diagnosis 5.2.4 Market Opportunity Analysis 5.3 HCV - Hepatitis C 5.3.1 Taxonomy 5.3.2 Structure 22.214.171.124 Genome 5.3.3 Molecular biology 5.3.4 Replication 5.3.5 Genotypes 126.96.36.199 Clinical importance 5.3.6 Market Opportunity Analysis 5.4 HPV - Human papillomavirus 5.4.1 Virology 188.8.131.52 E6/E7 proteins 184.108.40.206 Role in cancer 220.127.116.11 E2 research 18.104.22.168 Latency period 22.214.171.124 Clearance 5.4.2 Diagnosis 126.96.36.199 Cervical testing 188.8.131.52 Oral testing 184.108.40.206 Testing men 220.127.116.11 Other testing 5.4.3 Market Opportunity Analysis 5.5 Influenza 5.5.1 Virology 18.104.22.168 Types of virus 22.214.171.124 Influenzavirus A 126.96.36.199 Influenzavirus B 188.8.131.52 Influenzavirus C 184.108.40.206 Structure, properties, and subtype nomenclature 220.127.116.11 Replication 5.5.2 Testing 18.104.22.168 Advantages/Disadvantages of Molecular Assays 5.5.3 Market Opportunity Analysis 5.6 CTGC - Chlamydia/Gonorhea 5.6.1 Gonorrhea 22.214.171.124 Diagnosis 126.96.36.199 Screening 5.6.2 Chlamydia 188.8.131.52 Diagnosis 184.108.40.206 Screening 5.6.3 Testing 220.127.116.11 Nucleic acid amplification tests (NAATs) 18.104.22.168 Performance of NAAT Tests 5.6.4 Market Opportunity Analysis 5.7 Tuberculosis 5.7.1 Mycobacteria 5.7.2 Diagnosis 22.214.171.124 Active tuberculosis 126.96.36.199 Latent tuberculosis 5.7.3 Epidemiology 5.7.4 Molecular Diagnostic Tests 5.7.5 Market Opportunity Analysis 5.8 MRSA - Methicillin-resistant Staphylococcus aureus 5.8.1 Diagnosis 5.8.2 FDA Approved Molecular Tests 5.8.3 Market Opportunity Analysis 5.9 VRE - Vancomycin-resistant Enterococcus 5.9.1 FDA Approved MDx Tests for VRE 5.9.2 Market Opportunity Analysis 5.10 Blood Screening 5.10.1 Collection and Testing 5.10.2 FDA Approved Multiplex Assays 5.10.3 Market Opportunity Analysis 5.11 COVID-19 5.11.1 Signs and symptoms 5.11.2 Transmission 5.11.3 Diagnosis 5.11.4 Prevention 5.11.5 Management 5.11.6 Prognosis 5.12 Pandemic Diagnostics 5.12.1 Risk Management - Spark and Spread 5.12.2 Dx Technology - Nucleic Acid Based 5.12.3 Dx Technology - Immunoassay & Serology 5.12.4 Time to Market and Preparedness Issues 5.12.5 Unrecognized Role of Multiplex in Pandemic Management
6 Industry Overview 6.1 Players in a Dynamic Market 6.1.1 Academic Research Lab 6.1.2 Diagnostic Test Developer 6.1.3 Instrumentation Supplier 6.1.4 Distributor and Reagent Supplier 6.1.5 Independent Testing Lab 6.1.6 Public National/Regional Lab 6.1.7 Hospital lab 6.1.8 Physician Office Labs 6.1.9 Audit Body 6.1.10 Certification Body 6.2 The Clinical Laboratory Market Segments 6.2.1 Traditional Market Segmentation 6.2.2 Laboratory Focus and Segmentation 6.3 Industry Structure 6.3.1 Hospital Testing Share 6.3.2 Economies of Scale 188.8.131.52 Hospital vs. Central Lab 6.3.3 Physician Office Labs 6.3.4 Physicians and POCT
8 Market Trends 8.1 Factors Driving Growth 8.1.1 New Genotypes Creating New Markets 8.1.2 Aging Population a Boon for All Diagnostics 8.1.3 Developing World Driving ID Dx Growth 8.1.4 Point of Care - Why Centralization is Losing Steam 8.1.5 Self Testing 8.1.6 The Need for Speed 8.1.7 The COVID Pandemic 8.2 Factors Limiting Growth 8.2.1 Lower Costs 8.2.2 Infectious Disease is Declining 8.2.3 Wellness Hurts 8.2.4 Economic Growth improves Living Standards 8.3 Instrumentation and Automation 8.3.1 Instruments Key to Market Share 8.3.2 The Shrinking Machine 8.3.3 Multiplex, Point of Care and The Speed Factor 8.4 Diagnostic Technology Development 8.4.1 The Sepsis Testing Market - A New Direction? 8.4.2 POCT/Self Testing as a Disruptive Force 8.4.3 The Genetics Play - One Test for All Known Infections 8.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics
9 Molecular Dx - Infectious Disease Recent Developments 9.1 Recent Developments - Importance and How to Use This Section 9.1.1 Importance of These Developments 9.1.2 How to Use This Section 9.2 Roche to Acquire GenMark Diagnostics for $1.8B 9.3 Lucira Health Focuses on User Friendly Approach to Home Testing 9.4 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO 9.5 Fluidigm Plans 'Durable' Diagnostics, Clinical Business 9.6 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M 9.7 Mammoth Biosciences Developing Pathogen Detection Tech 9.8 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests 9.9 Scanogen Developing 90 Minute Infection Test 9.10 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection 9.11 FDA Provides Self Testing SARS-CoV-2 EAU Guidance 9.12 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic 9.13 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test 9.14 Qiagen Respiratory Panel with Coronavirus Receives CE Mark 9.15 Lumos Diagnostics Closes $15M Series A Funding 9.16 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay 9.17 New Genomic Tests Diagnose Deadly Infections Faster 9.18 Biotia Raises $2.4M Seed Round 9.19 STDs resurge in US 9.20 Ares Genetics signs R&D agreement with leading global IVD corporation 9.21 Cell-Free DNA Used for Infectious Disease Testing 9.22 One BioMed Raises $5M